Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Assets (2020 - 2025)

Oncology Institute (TOI) has disclosed Non-Current Assets for 6 consecutive years, with $53.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 14.71% year-over-year to $53.5 million, compared with a TTM value of $226.0 million through Sep 2025, down 11.45%, and an annual FY2024 reading of $60.3 million, down 8.29% over the prior year.
  • Non-Current Assets was $53.5 million for Q3 2025 at Oncology Institute, down from $55.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $230.3 million in Q1 2021 and bottomed at $49.4 million in Q4 2021.
  • Average Non-Current Assets over 5 years is $102.3 million, with a median of $65.7 million recorded in 2023.
  • Peak annual rise in Non-Current Assets hit 165.77% in 2022, while the deepest fall reached 71.05% in 2022.
  • Year by year, Non-Current Assets stood at $49.4 million in 2021, then soared by 165.77% to $131.2 million in 2022, then tumbled by 49.91% to $65.7 million in 2023, then decreased by 8.29% to $60.3 million in 2024, then decreased by 11.23% to $53.5 million in 2025.
  • Business Quant data shows Non-Current Assets for TOI at $53.5 million in Q3 2025, $55.0 million in Q2 2025, and $57.2 million in Q1 2025.